UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________________________________________

FORM 8-K

___________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 245, 2025

___________________________________________________

XENCOR, INC.

(Exact name of registrant as specified in its charter)

___________________________________________________

Delaware	001-36182	20-1622502
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

465 North Halstead Street, Suite 200 Pasadena, California						91107
(Address of Principal Executive Offices)						(Zip Code)
(Address of principal executive offices)						(Zip Code)

(626) 305-5900

(Registrant’s telephone number, including area code)

~~(Former name or former address, if changed since last report)~~N/A

(Former name or former address, if changed since last report.)

___________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	XNCR	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 72.0102. ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

On November 5, 2025, Xencor, Inc. (the “Company”) ~~held~~announced aits ~~conference~~financial ~~call on October 24, 2025 to discuss initial~~ results ~~from~~for the ~~ongoing~~third ~~Phase~~quarter 1ended ~~dose-escalation study of XmAb819 (ENPP3 x CD3)~~September 30, ~~early~~2025 ~~data~~in ~~from~~ the ~~ongoing~~press ~~Phase~~release 1attached ~~dose-escalation~~hereto ~~study~~as ofExhibit ~~XmAb541~~99.1 ~~(CLDN6 x CD3),~~ and ~~associated~~incorporated ~~near-term~~herein ~~clinical~~by ~~timelines~~reference. ~~The Company has also made available on its website (www.xencor.com) presentation materials containing certain data from the ongoing clinical studies and certain forward-looking information.~~

The information ~~contained~~ in, or“Item ~~that~~2.02. ~~can~~Results beof ~~accessed~~Operations ~~through,~~and ~~the~~Financial ~~Company’s~~Condition” ~~website~~of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not abe ~~part~~deemed ofto ~~this~~be ~~filing.~~“filed” Afor ~~copy~~purposes of Section 18 of the ~~presentation~~Securities isExchange ~~furnished~~Act of 1934, as ~~Exhibit~~amended ~~99.1~~(the “Exchange Act”), or otherwise subject to ~~this~~the ~~Current~~liabilities ~~Report~~of onthat ~~Form~~section, ~~8-K~~nor ~~and~~shall ~~incorporated~~such ~~herein~~information be deemed incorporated by reference. ~~The~~in ~~presentation~~any isfiling ~~current~~under asthe ofSecurities ~~April~~Act 29of 1933, ~~2025~~as ~~and~~amended, or the ~~Company~~Exchange ~~disclaims~~Act, ~~any~~except ~~obligation~~as toexpressly ~~update~~set ~~this~~forth ~~material~~by specific reference in such a filing.

On October 24, 2025, the Company issued a press release announcing the initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3) and associated near-term clinical timelines. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.			Description
99.1			~~Presentation~~Press ~~dated~~Release ~~October~~issued 24by Xencor, Inc. on November 5, 2025.
99.2			Press release issued by Xencor, Inc. on October 24, 2025.
104			Cover Page Interactive Data File (formatted as inline XBRL).
104			Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 24, 2025	XENCOR, INC.
Date: November 5, 2025	XENCOR, INC.
	By:	/s/ Celia Eckert
		Celia Eckert
		General Counsel & Corporate Secretary

Filing Compare · Xencor Inc